Current Report Filing (8-k)
March 09 2017 - 3:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 8, 2017
Sage Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
DELAWARE
|
|
001-36544
|
|
27-4486580
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
215 First Street
Cambridge, MA
|
|
02142
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (617) 299-8380
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On March 8, 2017, Howard Pien informed the Board of Directors (the Board) of Sage Therapeutics, Inc. (the
Company) of his intention not to stand for re-election at the Companys 2017 Annual Meeting of Shareholders (the Annual Meeting), and to retire from the Board effective immediately prior to the commencement of the Annual
Meeting. Mr. Piens decision not to stand for reelection was not a result of any dispute or disagreement with the Company or the Board.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: March 9, 2017
|
|
|
|
SAGE THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Anne Marie Cook
|
|
|
|
|
|
|
Anne Marie Cook
Senior Vice President, General
Counsel
|
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From Apr 2024 to May 2024
Sage Therapeutics (NASDAQ:SAGE)
Historical Stock Chart
From May 2023 to May 2024